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Abstract Estrogen as a potential factor of ovarian carci-
nogenesis, acts via two nuclear receptors, estrogen receptor
alpha (ERα) and estrogen receptor beta (ERβ), but the
cellular signal pathways involved are not completely clear
so far. In this study we have described the expression of
ERα, detected by immunocytochemistry in 11 ovarian
carcinoma cell lines and by immunohistochemistry in 43
Federation Internationale des Gyneacologistes et Obstetri-
stes stage III ovarian carcinoma specimens prepared before
and after treatment with cisplatin-based schemes. For
cisplatin resistance is a major obstacle in the treatment of
ovarian carcinoma, analysis of cisplatin sensitivity in 11
ovarian carcinoma cell line was also performed. The strong
nuclear ERα expression was only shown in the single
A2780P cell line. Expression of ERα in tissue specimens
did not reveal any correlations between histopathological
parameters (histologic type and grading). We demonstrated
a significant association with ERα expression in specimens
from primary laparotomies (PL) and cause–specific surviv-
al. In the cases terminated by death of the patient, overall
immunoreactivity score of ERα expression at PL was
significantly lower than in surviving patients. In addition,
Kaplan-Meier analysis revealed significantly shorter
overall survival time and progression-free time in cases
with lower immunoreactivity score of ERα expression at
PL. Our findings support the hypothesis that aberrant
hormone activity, by way of altered receptor expression,
might be an important factor in the malignant transfor-
mation of ovarian cancer.
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Ovarian cancer is the leading cause of death from
gynecological malignancies in Western countries. About
190,000 new cases and 114,000 deaths from ovarian cancer
are estimated to occur annually. The highest rates are
reported in Scandinavia and Eastern Europe, the USA, and
Canada [1]. One of the reasons for the poor prognosis is
high rate of advanced tumors at the time of diagnosis: about
75% of all patients are diagnosed in FIGO stage III or IV.
High serum levels of estrogen have been implicated as a
risk factor for ovarian carcinoma, but the cellular signal
pathways involved are not completely clear so far. The
most commonly considered hypothesis of ovarian carcino-
genesis proposes that incessant ovulatory cycles lead to
long-term exposure of the epithelium to an estrogen-rich
enviroment, which may promote cellular proliferation,
inclusion cyst formation, and possibly malignant transfor-
mation [2].
Estrogen acts via two nuclear receptors, estrogen
receptor alpha (ERα) and estrogen receptor beta (ERβ)
which are coded from two separate genes, ERα and ERβ,
located on chromosomes 6q25.1 and 14q22-24, respective-
ly [3]. Previous studies of normal and malignant human
ovaries have provided incoherent results. Pujol et al. [4]
have showed an increase in ERα mRNA relative to ERβ in
ovarian cancer compared to normal tissue. Another study
has revealed lower levels of ERβ in ovarian epithelial
primary tumors, and only ERα in metastatic tumors [5].
Substantially, many studies have demonstrated that ERβ is
highly represented in normal epithelial ovarian cells or
benign tumors [4, 6–8], whereas ERα is the main form
expressed in malignant tumors [6]. Further studies are
needed to fully determine the contributions of ERs to
ovarian cancer.
Only 15–18% of ER-positive ovarian cancer initially
respond to anti-estrogen treatment based on blocking of
estrogen-ER binding, in contrast to effective treatment of
about 50% of ER-positive breast cancer [9]. The most
common mechanism of antiestrogen resistance is absence
of estrogen receptors. From the previous data, the role of
tamoxifen in ovarian cancer has not been properly
evaluated, although some authors postulated that combined
therapy with cisplatin and tamoxifen might reduced
cisplatin resistance [10, 11]
Material and Methods
Cell Culture
Human carcionoma cells were grown in Leibovitz L-15
medium (Biowhittaker, Walkersville, MD) supplemented
by 10% fetal calf serum (FCS) (GIBCO/BRL, Grand
Island, NY), 1 mM L-glutamine, 6.25 mg/l fetuin,
80 IE/l insulin, 2.5 mg/ml transferrin, 0.5 g/l glucose,
1.1 g/l NaHCO3, 1% minimal essential vitamins and
20,000 kIE/l trasylol in a humidified atmosphere of 5%
CO2 at 37°C as described previously [12–15]. The
cisplatin-resistant cell line, A2780RCIS, was derived from
the ovarian carcinoma cell line, A2780 [12]. The human
ovarian carcinoma cell lines CAOV-3, EFO 21, EFO 27, ES-
2, Mdah 2774, OAW 42, OVCAR-3, PA-1, and SKOV-3
were kindly provided by Dr. Carsten Denkert (Institute of
Pathology, Charité, Berlin, Germany). In order to ensure
maintenance of cisplatin-resistant phenotype of A2780RCIS
cells, the medium was supplemented with 10 Ag/mL of
cisplatin (33.3 μmol/L; GRY-Pharm, Kirchzarten, Germany).
Cell Proliferation Assay
Chemoresistance was tested using a proliferation assay
based on sulphorhodamine B (SRB) staining as described
previously [16]. Briefly, 800 cells per well were seeded in
96-well plates in triplicates. After 24 h attachment, cisplatin
(GRY-Pharm, Kirchzarten, Germany) was added in dilution
series for a 5-day incubation, before SRB staining was
performed. Incubation with cisplatin was terminated by
replacing the medium with 10% trichloroacetic acid,
followed by incubation at 4°C for 1 h. Subsequently, the
plates were washed five times with water and stained by
adding 100 μl 0.4% SRB (Sigma, St. Louis, MO, USA) in
1% acetic acid for 10 min at room temperature. Washing the
plates five times with 1% acetic acid eliminated unbound dye.
After air-drying and re-solubization of the proteinbound dye
in 10 mM Tris-HCl (pH=8.0) absorbance was read at 562 nm
in an Elisa-Reader (EL 340 Microplate Bio Kinetics Reader,
BIO-TEK Instruments, Winooski, VT, USA). The measure-
ments were performed in triplicates in three independent
experiments. IC50-values were calculated from three inde-
pendent experiments for each cell line.
Patients
Immunohistochemical examination was performed retro-
spectively on tissue samples taken for routine diagnostic
purposes. Forty three patients operated in 1999–2002 due to
ovarian carcinoma in the Department of Gynaecology and
Obstetrics, University Medical School in Poznan, Poland
were included in the study. The cases were selected based
on availability of tissue and were not stratified for known
preoperative or pathological prognostic factors. The study
was approved by an Institutional Review Board (IRB) and
the patients gave their informed consent before their
inclusion into the study. Following the primary laparotomy
(PL) all the patients were subjected to chemotherapy using
512 A. Halon et al.cisplatin-based schemes (Table 1). Thirty six patients from
the same group were subjected also to the secondary
cytoreduction (SCR). In 7 cases no second-look procedure
was performed due to advancement of the disease. In 6
cases no tumour cells were detected in the material
originating from the second-look procedure. The patients
were monitored by periodic medical check-ups, CA-125
serum levels, ultrasonographic and radiological examina-
tions. During the follow-up period, 22 patients (51%) had a
recurrent disease and 13 patients (30%) died of the disease.
The mean (median) progression-free survival time was
16.9 months (range 0–52 months), while the mean (median)
overall-free survival time was 24.6 months (range 6–
52 months). Only 1 stage I and 1 stage II patients achieved
optimal cytoreduction.
Tissue samples were fixed in 10% buffered formalin and
embedded in paraffin. In each case, hematoxylin and eosin
stained preparations were subjected to histopathological
evaluation by two pathologists. The stage of the tumors was
assessed according to the International Federation of
Gynaecology and Obstetrics [17]. Tumors were graded
according to the Silverberg grading system [18].
Immunohistochemistry
Formalin-fixed, paraffin embedded tissue was freshly cut
(4 μm). The sections were mounted on Superfrost slides
(Menzel Gläser, Germany), dewaxed wtih xylene, and gradu-
ally hydrated. Activity of endogenous peroxidase was blocked
by 5 min exposure to 3% H2O2. All the studied sections were
boiled for 15 min at 250 W in the Antigen Retrieval Solution
(DakoCytomation, Denmark). Then, immunohistochemical
reactions were performed using the mouse monoclonal
(clone 1D5) antibodies detecting ERα (optimaly prediluted)
(DakoCytomation, Denmark). Tested sections were incubated
with antibodies for 1 h at room temperature. Subsequent
incubations involved biotinylated antibodies (15 min, room
temperature) and streptavidin-biotinylated peroxidase complex
(15 min, room temperature) (LSAB+, HRP, DakoCytomation,
Denmark). NovaRed (Vector Laboratories, UK) was used as a
chromogen (10 min, at room temperature). All the sections
were counterstained with Meyer’s hematoxylin. On every
case, control reactions were included, in which specific
antibody was substituted by the Primary Mouse Negative
Control (DakoCytomation, Denmark).
Control reactions were also performed on paraffin
sections from six breast cancer cases, known as estrogen
receptor positive (from the archive of the Department of
Pathology, Lower Silesian Centre of Oncology).
Immunocytochemistry
Immunostaining of ERα was performed using all the
studied cell lines. Cells were grown on microscope slides
and fixed in ice-cold methanol-acetone mixture (1:1) for
10 min. After re-hydration, immunostaining reaction was
performed in triplicate as described above.
Evaluation of Reaction Intensity
Intensity of immunohistochemical reactions was estimated
independently by two pathologists. In doubtful cases a re-
evaluation was performed using a double-headed microscope
and staining was discussed until a consensus was achieved. In
ordertoevaluatetheERαexpressionasemi-quantitativescale
of ImmunoReactive Score (IRS) was applied, in which
intensity of colour reaction and percentage of positive cells
were taken into account. The score represented a product of
points given for the evaluated characters and it ranged from 0
to 12 [19]( T a b l e2). Cases with expression of 0 to 2 in IRS
scale [19–21] were treated as negative cases.
Statistical Analysis
Statistical analysis of the results took advantage of
Statistica 98 PL software (Statsoft, Poland). The employed
Table 1 Patient and tumor characteristics
Characteristics No. (%)
c
All patients 43 (100)
Age (mean 51.0)
a ≤50 20 (47)
50–60 16 (37)
>60 7 (16)
Grade
a 1 7 (16)
2 18 (42)
3 18 (42)
FIGO
a I 1 (2)
II 1 (2)
III 41 (95)
Histology
a Serous 37 (86)
Endometrioid 3 (7)
Other 3 (7)
Clinical response
b Complete response 16 (37)
Stable disease 5 (12)
Progressive disease 22 (51)
Chemotherapy
(in total)
Cisplatin/Paclitaxel 31 (72)
Cisplatin/Cyclophosphamide/
Adriblastin
6 (14)
Cisplatin/Cyclophosphamide/
Paclitaxel
3 (7)
Cisplatin/Cyclophosphamide/
Paclitaxel/Adriblastin
2 (5)
Carboplatin/Paclitaxel 1 (2)
aData are given for the first operation/diagnosis implemented
bAccordingtoRECIST(ResponseEvaluationCriteriainSolidTumours)[29]
cDifferences in the sum to 100% in groups are due to rounding
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2. Kaplan-
Meier’s statistics and log-rank tests were performed using
SPSS software (release 10.0; SPSS Inc., Chicago, IL, USA)
to estimate significance of differences in survival times.
The length of progression-free survival was defined as
the time between the primary surgical treatment and
diagnosis of a recurrent tumor or death. Since we have
not found with an univariate analysis any significant
relationships between studied clinicopathological param-
eters (age, histology, grade, CA-125 at PL level) and
overall survival and progression free time of studied
patients (P> 0 . 0 5 ) ,w eh a v en o tp e r f ormed a multivariate
analysis. Since 95% of the studied patients were in stage
FIGO III, we have not investigated relationships between
stage and survival data.
We have also performed Kaplan-Meier’s statistics and
log-rank tests on subgroup of 35 FIGO III patients
receiving post-surgical platinum and paclitaxel containing
combination therapy.
Results
Cisplatin-Sensitivity of Studied Cell Lines
Table 3 shows IC50 values of studied cell lines for cisplatin
(Table 3).
The studied ovarian carcinoma cells have shown a
broad variety of cisplatin-sensitivity. Majority of them
showed a relatively good response to the cisplatin, with
the exception of the A2780RCIS, A2780P and SKOV-3
cell lines (IC50=98.98, 23.87 and 18.85 respectively).
ERα Immunostaining in Studied Cell Lines
We have shown the strong nuclear expression (score 12)
ERα in A2780P cell line. The other studied cell lines were
ERα negative. So, we have not studied the relationships
between ERα expression and cisplatin-sensitivity of studied
cell lines.
ER Immunostaining in Control Preparations and in Ovarian
Cancers
Control reactions performed on the sections of human breast
cancers demonstrated a strong reaction of nuclear localisation
in neoplastic cells. In the case of studied ovarian cancers,
reactionofnuclearlocationwas obtained,ofvariableintensity
in individual cases (Fig. 1a and b). Mean overall immuno-
reactivity score of ERα expression amounted to 2,837±
2,894 SD (min. 0, max. 12) in PL material and 2,533±2,738
SD (min. 0, max. 12) in SCR material (Fig. 2).
At the first stage of statistical analysis the Mann-
Whitney’s U test was employed to compare overall
immunoreactivity score of ERα expression at PL and
SCR. We have found no significant differences (P>0.05).
Using the Chi
2 test, relationships were examined
between overall immunoreactivity score of ERα expression
on one hand and histological type of the tumour and grade
on the other. No significant relationships were detected
(Table 4). Spearman’s rank correlation demonstrated no
relationships between overall immunoreactivity score of
ERα expression at PL and at SCR on one hand and patients
age on the other (Table 4).
ER Expression and Patients Survival
At the first stage of statistical analysis of relationships
between ERα expression and survival of the patients, Chi
2
test was used. The relations were examined between overall
immunoreactivity score of ERα expression on one hand
Table 3 Chemosensitivity to cisplatin (IC50 value) and immunoreac-
tivity score of ERα expression in human ovarian carcinoma cell lines
Cell line IC50 [μM] ERα [IRS score]
A2780P 23.87 12
A2780RCIS 98.98 0
CAOV-3 1.92 0
EFO 21 5.08 0
EFO 27 2.25 0
ES-2 7.64 0
Mdah 2774 6.36 0
OAW 42 5.49 0
OVCAR-3 1.88 0
PA-1 0.75 0
SKOV-3 18.85 0
Percentage of positive cells Points Intensity of reaction Points
No positive cells 0 No reaction 0
<10% positive cells 1 Weak colour reaction 1
10–50% positive cells 2 Moderate intensity 2
51–80% positive cells 3 Intense reaction 3
>80% positive cells 4
Table 2 Procedure for evalua-
tion of estrogen receptor alpha
expression using IRS
(ImmunoReactive Score)
score [19]
514 A. Halon et al.and clinical response to chemotherapy, relapses and patient
deaths on the other. In the cases terminated by death of the
patient overall immunoreactivity score of ERα expression
at PL was significantly lower (P=0.003) than that in
surviving patients (Table 4).
In Kaplan-Meier’s analysis overall survival time and
progression-free time were compared between cases show-
ing lower (IRS 0–2) and higher (IRS 3–12) overall
immunoreactivity score of ERα expression at PL and
SCR. The analysis demonstrated that significantly shorter
overall survival time and progression-free time character-
ized cases with lower overall immunoreactivity score of
ERα expression at PL (Fig. 3a and b). In sections
originating from SCR no significant relationship could be
detected between overall immunoreactivity score of ERα
expression and patients survival (Fig. 3c and d).
In the subgroup of 35 FIGO III patients receiving post-
surgical platinum and paclitaxel containing combination
therapy the analysis has shown no significant relationships
between ERα expression and overall survival time and
progression-free time (Table 5).
Discussion
In this study we have described the expression of ERα,
detected by immunohistochemistry in malignant epithelial
ovarian tumours, in the sections originating from primary
laparotomies and secondary cytoreductions.
Expression of ERα did not reveal any correlations
between histopathological parameters, such as histologic
type of tumors and ovarian cancer grading. Interestingly,
we demonstrated a significant association with ERα
expression in specimens from PL and cause–specific
survival. In the cases terminated by death of the patient,
overall immunoreactivity score of ERα expression at PL
was significantly lower than in surviving patients. In
addition, Kaplan-Meier analysis revealed significantly
shorter overall survival time and progression—free time in
cases with lower immunoreactivity score of ERα expres-
sion at PL. We have found no association between these
parameters and sections originating from SCR.
ERα expression has been studied extensively in ovarian
cancer to correlate it to clinico-pathological parameters and
prognosis [1, 3, 6, 22 24, 25]. Despite that, no clear
relationship between immunohistochemical status of ERα,
tumor parameters and outcome has been noted in ovarian
cancer.
Lee et al. [23] demonstrated that expression of receptors
for estrogen did not show an effect on survival, only
progesterone receptor (PR) was an independent marker,
with its overexpression associated with favorable prognosis
in patients with ovarian cancer.
Li et al. [24] made researches on ovarian cells cultures,
identified a 2-fold up-regulation of ERα protein that was
relative to ERβ in primary cells cultures, that are derived
from epithelial ovarian cancer. These finding reflect differ-
ences between normal and malignant primary cultures and
support an association between the up-regulation ERα in
ovarian carcinogenesis.
On the other hand, Hecht et al. [25] have revealed no
relationship between ERα expression and clinico-pathological
parameters, such as tumor invasion, grade and stage.
Our results presented here are in accordance with Burges
et al. [22], investigating ERα expression by immunohisto-
chemistry. In this study, univariate survival analysis
revealed that patients with positive-ERα status had a
significant better progression-free survival compared with
the patients with no expression. Additionally, patients with
Fig. 1 Immunohistochemical localisation of ERα expression in
ovarian cancer tissue (a., ×200, b., ×400; hematoxylin) and in the
cells A2780P (c., ×200; hematoxylin)
Estrogen Receptor Alpha Expression in Ovarian Cancer 515low immunoreactive score of ERα expression characterized a
highly significant poorer cause-specific survival. Interesting-
ly, high level of ERα expression demonstrated a significant
association with grading [22].
Despite several in vitro studies which investigated
ovarian cancer tissues and human ovarian cancer cell lines
exist [24–28], exact mechanism of ovarian tumorigenesis is
not well known. In our study, we have shown the strong
nuclear expression (score 12) ERα only in A2780P cell
line. The other studied cell lines were ERα negative.
Additionally, investigated cell lines have shown a broad
variety of cisplatin sensitivity. Majority of them revealed a
relatively good response to the cisplatin, with the exception
of the A2780RCIS, A2780P and SKOV-3 cell lines. So, we
have not studied the relationship between ERα expression
and cisplatin sensitivity of studied cell lines.
Conflicting effects from various studies and clinical
trials about role of ERα in ovarian carcinogenesis may
come from differences in methodology and existence of
undefined factors, which are involved in tumor progression.
Intriguing results documenting estrogen impact on ovarian
cancer and significance of ERα expression in promotion of
tumor progression have Chao et al [27]. They investigated
potential role of estrogen and progesterone in the OC-117-
Fig. 2 Expression of ERα a
at primary laparotomy and b at
secondary cytoreduction and
clinical and pathological data on
the patients. CR:complete
response, SD stable disease, PD
progressive disease
Table 4 Correlation between estrogen receptor alpha expression and
various clinicopathologic parameters
Characteristics Primary laparotomy
(PL) P value Chi
2 test
Secondary cytoreduction
(SCR) P value Chi
2 test
Histologic type 0.4271 –
Grade
a 0.2768 –
Clinical response 0.5367 0.6557
Age
b 0.1343 0.7992
Relapse 0.2697 0.9657
Death 0.0443 0.2888
PL first-look laparotomy; SCR secondary cytoreductions
aThe relationships between ER expression at SCR on one hand and
histologic type and grade on the other was not examined
bSpearman’s rank correlation
516 A. Halon et al.VGH human ovarian adenocarcinoma cell line, which was
negative for ERα,E R β and PR. Furthermore, serial concen-
trations of estrogen and progesterone were used to evaluate
their effects on the survival of ovarian cancer cell line.
Paradoxically,these resultsshowedthatthe OC-117-VGHcell
line was sensitive to estrogen inhibition of growth and
proliferation through down-regulation of anti- and pro-
apoptotic genes Bcl-2 and Bax. This phenomenon was
definitely associated with ERα-independent pathway. Inter-
estingly, estrogen treatment in this cell line had a negative
effect on tumor survival, so estrogen may also directly affects
cell growth and proliferation without binding to its relevant
receptor ERα [27]. In the light of this experimental results,
further studies are needed to fully determine the contribution
of estrogen and ERα to ovarian cancer.
However, it should be noted that high expression of ERα
as a important factor that could be responsible for
promoting ovarian tumor progression, have been reported
in previous studies [1, 2, 26, 28]. Park et al. [28]
additionally revealed that 17β-estradiol (E2) treatment,
exclusively through an ERα-dependent pathway led to
increasing the metastatic propensity of human epithelial
ovarian cancer cell lines and enhanced cell migratory
potential. This cytomorphological and functional alterations
were significantly associated with up-regulation of Snail
and Slug—the leading epithelial-mesenchymal transition
(EMT) transcription factors, and down-regulation of
E-cadherin as a one of the best-characterized markers of
EMT and tumor suppressor. This study provides that
ovarian carcinogenesis is a multistep process, in which are
involved a lot of biological factors and ERα can potentiate
tumor progression by EMT induction.
Fig. 3 Kaplan-Meier curves for
survival and expression of ERα
in studied group of 43 ovarian
cancer patients: Patients with
higher overall immunoreactivity
score of ERα expression at PL
have an increased overall sur-
vival time (a) and an increased
progression-free time (b). No
significant differences in overall
survival time (c) and
progression-free time (d) be-
tween patients with lower and
higher overall immunoreactivity
score of ERα expression at SCR
Table 5 Relationships between overall survival time (OS) and
progression-free survival (PFS) and expression of ERα in the
subgroup of FIGO stage III patients treated with platinum-based
drugs and paclitaxel
PL, n=35 SCR, n=24
Score Score 0–2 n=18 Score 0–2n = 1 5
Score 3–12 n=17 Score 3–12 n=9
Overall survival P=0.2352 P=0.0633
Progression-free survival P=0.1894 P=0.7324
Estrogen Receptor Alpha Expression in Ovarian Cancer 517Possibly way of explanation this immunohistochemical
contradiction is fact that estrogens have a cancer-promoting
effect during early stage in ovarian carcinogenesis, but during
cancer progression other malignant factors might supplant
preponderant cancer-promoting role of ERα [22]. Our
findingssupportthehypothesisthataberranthormoneactivity,
by way of altered receptor expression, might be an important
factor in the malignant transformation of ovarian cancer.
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